Alexion Pharmaceuticals (NASDAQ:ALXN) has been given a $172.00 price target by SunTrust Banks in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price target would indicate a potential upside of 58.38% from the company’s previous close.

Several other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Robert W. Baird upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 target price for the company in a research note on Monday, December 18th. Royal Bank of Canada raised their target price on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $152.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $0.13 during mid-day trading on Monday, hitting $108.60. 3,039,200 shares of the stock traded hands, compared to its average volume of 2,023,806. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34. The firm has a market cap of $24,260.00, a PE ratio of 55.13, a PEG ratio of 0.95 and a beta of 1.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the business earned $1.26 EPS. The business’s revenue was up 9.5% on a year-over-year basis. equities research analysts forecast that Alexion Pharmaceuticals will post 6.25 earnings per share for the current year.

In other Alexion Pharmaceuticals news, CFO Paul J. Clancy sold 6,079 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $707,048.49. Following the completion of the transaction, the chief financial officer now directly owns 95,093 shares in the company, valued at approximately $11,060,266.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The disclosure for this sale can be found here. Insiders sold a total of 28,930 shares of company stock valued at $3,378,199 in the last quarter. Insiders own 4.35% of the company’s stock.

A number of large investors have recently bought and sold shares of ALXN. Dimensional Fund Advisors LP increased its holdings in Alexion Pharmaceuticals by 13.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 364,268 shares of the biopharmaceutical company’s stock valued at $44,323,000 after acquiring an additional 42,809 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in Alexion Pharmaceuticals by 1.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 151,163 shares of the biopharmaceutical company’s stock valued at $18,392,000 after acquiring an additional 2,394 shares in the last quarter. WINTON GROUP Ltd purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $296,000. Toronto Dominion Bank increased its holdings in Alexion Pharmaceuticals by 25.5% during the 2nd quarter. Toronto Dominion Bank now owns 76,071 shares of the biopharmaceutical company’s stock valued at $9,254,000 after acquiring an additional 15,464 shares in the last quarter. Finally, Aldebaran Financial Inc. purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $426,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://theolympiareport.com/2018/02/12/alexion-pharmaceuticals-alxn-pt-set-at-172-00-by-suntrust-banks.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.